A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma
Latest Information Update: 22 Mar 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 18 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2023 Planned number of patients changed from 32 to 13.
- 18 Oct 2022 Planned primary completion date changed from 1 Sep 2024 to 1 Mar 2024.